A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model
Publication date: Available online 23 September 2020Source: CellAuthor(s): Jakob Kreye, S. Momsen Reincke, Hans-Christian Kornau, Elisa Sánchez-Sendin, Victor Max Corman, Hejun Liu, Meng Yuan, Nicholas C. Wu, Xueyong Zhu, Chang-Chun D. Lee, Jakob Trimpert, Markus Höltje, Kristina Dietert, Laura Stöffler, Niels von Wardenburg, Scott van Hoof, Marie A. Homeyer, Julius Hoffmann, Azza Abdelgawad, Achim D. Gruber
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
Publication date: Available online 10 October 2020Source: Journal of Hospital InfectionAuthor(s): Hisakazu Yano, Ryuichi Nakano, Yuki Suzuki, Akiyo Nakano, Kei Kasahara, Hiroshi Hosoi
Authors: Yepes-Pérez AF, Herrera-Calderon O, Sánchez-Aparicio JE, Tiessler-Sala L, Maréchal JD, Cardona-G W Abstract COVID-19 is a disease caused by severe acute respiratory syndrome coronavirus 2. Presently, there is no effective treatment for COVID-19. As part of the worldwide efforts to find efficient therapies and preventions, it has been reported the crystalline structure of the SARS-CoV-2 main protease Mpro (also called 3CLpro) bound to a synthetic inhibitor, which represents a major druggable target. The druggability of Mpro could be used for discovering drugs to treat COVID-19. A multil...
Conclusions: Early results of universal preoperative screening for COVID-19 demonstrates a low incidence and high rate of asymptomatic patients. Health care professionals, especially those at higher risk for the virus, should be aware of the challenges related to screening based solely on symptoms or travel history and consider universal screening for patients undergoing elective surgery. Level of Evidence: Level II.
The case offers proof that "SARS-CoV-2 can also infect ocular tissues in addition to the respiratory system," the doctors reported in the Oct. 8 online edition of the journal JAMA Ophthalmology.
Publication date: Available online 9 October 2020Source: Journal of Hospital InfectionAuthor(s): Makoto Hibino, Shogo Iwabuchi, Hiromi Munakata
To investigate the relationship between maximal exercise capacity measured before severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and hospitalization due to coronavirus disease 2019 (COVID-19).
We present the case of a very rapid neurologic and radiographic decline of a patient with an acute ischemic stroke who developed rapid fulminant cerebral edema leading to herniation in the setting of hypercarbic respiratory failure attributed to SARS-CoV-2 infection.
After being epidemic in China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) infection has rapidly spread in many countries as a global pandemic, with the number of affected cases dramatically increasing worldwide on a daily basis. Although the median age of hospitalized patients with confirmed infection is usually more advanced 1, with older age reported to be associated to higher mortality rate 2, physiological adaptations occurring during pregnancy have been claimed to be potentially responsible for a more severe respiratory disease, thus leading to higher rates of maternal and fetal complications 3,4.